Skip to main content

TFS was selected as the rescue CRO to provide services for a biotech/clinical research center collaboration, to develop topical therapy for neurodegeneration, as an early event in the pathogenesis of diabetic retinopathy (DR). Eligible patients were randomized in a 1:1:1 ratio to one of three treatment arms.